Literature DB >> 6454484

Iv dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation.

A I Cohen, J Koeller, T E Davis, D L Citrin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6454484

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  6 in total

1.  A model of localized osteolysis induced by the MBT-2 tumor in mice and its responsiveness to etidronate disodium.

Authors:  R Nemoto; K Uchida; M Tsutsumi; K Koiso; S Satou; T Satou
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

Review 2.  Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

Authors:  N Zojer; A V Keck; M Pecherstorfer
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 3.  Clodronate in hypercalcemia of malignancy.

Authors:  J P Bonjour; R Rizzoli
Journal:  Calcif Tissue Int       Date:  1990       Impact factor: 4.333

4.  Influence of dichloromethylene bisphosphonate on the in vitro phagocytosis of hydroxyapatite particles by rat peritoneal exudate cells: an electron microscopic and chemiluminescence study.

Authors:  P M Hyvönen; M J Kowolik
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

5.  Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.

Authors:  Z Nesković-Konstantinović; L Mitrović; J Petrović; L Stamatović; Z Ristović
Journal:  Support Care Cancer       Date:  1995-11       Impact factor: 3.603

Review 6.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.